Hims & Hers Health Likely To Report Q2 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
HIMS to release Q2 earnings on Aug. 10, expected to report a loss of 5 cents/share. FDA panel voted to add BPC-157 to compounding list. Stock rose 6.5% on Friday.
Hims is expected to lose a small amount of money this quarter, but good news about a new medicine ingredient they can offer helped the stock go up. When a company has losses but good news too, it shows how people balance the bad with the hopeful.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.